Filters
Results 1 - 10 of 4411
Results 1 - 10 of 4411.
Search took: 0.028 seconds
Sort by: date | relevance |
AbstractAbstract
[en] Solitary fibrous tumors (SFTs) are extremely rare mesenchymal malignancies. Given the lack of large prospective studies on radiation therapy (RT) with definitive and/or palliative intent in SFT patients, this retrospective study aimed to better define the benefit of RT in this disease.
Primary Subject
Source
S0360301618306813; Available from http://dx.doi.org/10.1016/j.ijrobp.2018.04.024; Copyright (c) 2018 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
International Journal of Radiation Oncology, Biology and Physics; ISSN 0360-3016;
; CODEN IOBPD3; v. 101(5); p. 1226-1233

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Recent histological and molecular evaluation of lipo sarcomas led to the reclassification of this tumors group based on genetic markers. Molecular classification of lipo sarcomas is very important and now is considered to become an integral part of the WHO classification. It is supposed that additional information on molecular features of lipo sarcomas will allow exact sub classification and providing a platform for molecular therapy to be included in the current treatment approach. (author)
Original Title
Molekularna klasifikacia liposarkomov
Primary Subject
Source
20 refs., 4 figs.
Record Type
Journal Article
Journal
Onkologia (Bratislava); ISSN 1336-8176;
; v. 6(6); p. 367-370

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Venigalla, Sriram; Nead, Kevin T.; Sebro, Ronnie; Guttmann, David M.; Sharma, Sonam; Simone, Charles B.; Levin, William P.; Wilson, Robert J.; Weber, Kristy L.; Shabason, Jacob E., E-mail: Sriram.Venigalla@uphs.upenn.edu2018
AbstractAbstract
[en] Soft tissue sarcomas (STS) are rare malignancies that require complex multidisciplinary management. Therefore, facilities with high sarcoma case volume may demonstrate superior outcomes. We hypothesized that STS treatment at high-volume (HV) facilities would be associated with improved overall survival (OS).
Primary Subject
Source
S0360301617344838; Available from http://dx.doi.org/10.1016/j.ijrobp.2017.12.262; Copyright (c) 2017 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
International Journal of Radiation Oncology, Biology and Physics; ISSN 0360-3016;
; CODEN IOBPD3; v. 100(4); p. 1004-1015

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Canary, P.C.V.; Valente, M.S.S.
Proceedings of the 19. Meeting on Radiology from Rio de Janeiro and 12. Meeting of Radiology Residents from Rio de Janeiro1988
Proceedings of the 19. Meeting on Radiology from Rio de Janeiro and 12. Meeting of Radiology Residents from Rio de Janeiro1988
AbstractAbstract
[en] Published in summary form only
Original Title
Sarcomas de utero; estudo de 22 casos
Primary Subject
Source
Sociedade Brasileira de Radiologia, Sao Paulo, SP (Brazil); 43 p; 1988; p. 22; 19. Meeting on Radiology from Rio de Janeiro and 12. Meeting of Radiology Residents from Rio de Janeiro; 19. Jornada de Radiologia do Rio de Janeiro; Rio de Janeiro, RJ (Brazil); 16-19 Nov 1988
Record Type
Miscellaneous
Literature Type
Conference
Report Number
Country of publication
LanguageLanguage
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Motta, N.W. da; Barletta, A.; Vauthier, G.; Sandri, A.
Proceedings of the 2. Iberian-American Congress of Oncology1988
Proceedings of the 2. Iberian-American Congress of Oncology1988
AbstractAbstract
[en] Published in summary form only
Original Title
Sarcoma de Ewing
Primary Subject
Source
Sociedade Brasileira de Cancerologia, Salvador, BA (Brazil); 156 p; 1988; p. 138; 2. Iberian-American Congress of Oncology; Salvador, BA (Brazil); 9-14 Oct 1988
Record Type
Miscellaneous
Literature Type
Conference
Report Number
Country of publication
LanguageLanguage
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] A single fraction of 800 cGy was used in the treatment of acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma (KS). A total of 74 radiation treatments was given to a total of 31 patients. Of all 74 evaluable treatments, there were 25 objective major responses (6 complete, 19 partial) according to WHO criteria, while 67 treatments resulted in subjective palliation of the main reason to treat (cosmetic discomfort, pain, or oedema). However, it appeared that the duration of these responses was rather short; in 23 of 36 radiation treatments with a follow-up of more than 4 months, progression of the tumour was seen within that time, while the palliative effect outlasted the survival of the patients in only 4 cases. It is concluded that a single dose of 800 cGy is an effective treatment for patients with a predicted survival of only a few months, and it should be determined whether a higher fractionated dose improves duration of responses, especially for patients with a good performance. (author). 18 refs.; 1 tab
Primary Subject
Record Type
Journal Article
Journal
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Highlights: • Ddedifferentiated liposarcoma (DDLPS) is recalcitrant and has the lowest survival rate. • Determine the efficacy of rMETase combined with palbociclib (PAL) against a DOX-resistant DDLPS in a PDOX mouse model. • The combination of PAL and rMETase significantly regressed tumor volume. • The combination of rMETase and PAL could be developed clinically. Liposarcoma is the most common type of soft tissue sarcoma. Among the subtypes of liposarcoma, dedifferentiated liposarcoma (DDLPS) is recalcitrant and has the lowest survival rate. The aim of the present study is to determine the efficacy of metabolic targeting with recombinant methioninase (rMETase) combined with palbociclib (PAL) against a doxorubicin (DOX)-resistant DDLPS in a patient-derived orthotopic xenograft (PDOX) model. A resected tumor from a patient with recurrent high-grade DDLPS in the right retroperitoneum was grown orthotopically in the right retroperitoneum of nude mice to establish a PDOX model. The PDOX models were randomized into the following groups when tumor volume reached 100 mm3: G1, control without treatment; G2, DOX; G3, PAL; G4, recombinant methioninase (rMETase); G5, PAL combined with rMETase. Tumor length and width were measured both pre- and post-treatment. On day 14 after initiation, all treatments significantly inhibited tumor growth compared to the untreated control except DOX. PAL combined with rMETase was significantly more effective than both DOX, rMETase alone, and PAL alone. Combining PAL and rMETase significantly regressed tumor volume on day 14 after initiation of treatment and was the only treatment to do so. The relative body weight on day 14 compared with day 0 did not significantly differ between each treatment group. The results of the present study indicate the powerful combination of rMETase and PAL should be tested clinically against DDLPS in the near future.
Primary Subject
Source
S0006291X18322812; Available from http://dx.doi.org/10.1016/j.bbrc.2018.10.119; Published by Elsevier Inc.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Biochemical and Biophysical Research Communications; ISSN 0006-291X;
; CODEN BBRCA9; v. 506(4); p. 912-917

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] An analysis of a pilot study of neutron therapy of 70 patients with tissue sarcomas is presented. In a group of 50 patients who had undergone macroscopically or microscopically subtotal surgery, 44 (88 %) are free of recurrence after a mean follow-up period of 13,3 months (range: 4-30 months). In another group of patients who had partial tumour resection or only biopsies with gross tumour left behind, a local tumour control is seen in 8 cases (40 %). Despite these favourable results there is as yet no clinical evidence that neutron irradiation is superior to photon or electron irradiation in the postoperative treatment of soft tissue sarcomas. To clarify this question, an EORTC/RTOG trial is being planned
Primary Subject
Record Type
Journal Article
Journal
Journal Europeen de Radiotherapie; ISSN 0243-1203;
; v. 2(2); p. 119-122

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Gouw, Launce G.; Jones, Kevin B.; Sharma, Sunil; Randall, R. Lor, E-mail: launce.gouw@hsc.utah.edu2011
AbstractAbstract
[en] Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential efficacy of this treatment modality. The rarity and heterogeneity of tumors of mesenchymal origin continues to be a challenge from a therapeutic standpoint. Nonetheless, sarcomas remain attractive targets for immunotherapy, as they can be characterized by specific epitopes, either from their mesenchymal origins or specific alterations in gene products. To date, standard vaccine trials have proven disappointing, likely due to mechanisms by which tumors equilibrate with and ultimately escape immune surveillance. More sophisticated approaches will likely require multimodal techniques, both by enhancing immunity, but also geared towards overcoming innate mechanisms of immunosuppression that favor tumorigenesis
Primary Subject
Source
Available from http://dx.doi.org/10.3390/cancers3044139; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763415; PMCID: PMC3763415; PMID: 24213130; PUBLISHER-ID: cancers-03-04139; OAI: oai:pubmedcentral.nih.gov:3763415; Copyright (c) 2011 by the authors; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Cancers (Basel); ISSN 2072-6694;
; v. 3(4); p. 4139-4150

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
Schmitt, G.; Essen, C.F. von; Scherer, E.; Fuerst, G.
Third international meeting on progress in radio-oncology1985
Third international meeting on progress in radio-oncology1985
AbstractAbstract
No abstract available
Primary Subject
Source
Vienna Univ. (Austria). Klinik fuer Strahlentherapie und Strahlenbiologie; 88 p; 1985; p. 48; Third international meeting on progress in radio-oncology; Vienna (Austria); 27-30 Mar 1985; Published in summary form only.
Record Type
Miscellaneous
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
Related RecordRelated Record
INIS VolumeINIS Volume
INIS IssueINIS Issue
1 | 2 | 3 | Next |